About: A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus
Creator	Bernard, Julie Bernardet, Philippe Bernex, Florence Castagné, Nathalie Deplanche, Martine Deville, Sébastien Dubosclard, Virginie Dubuquoy, Catherine Durand, Guillaume Meyer, Gilles Petit-Camurdan, Agnès Riffault, Sabine Schwartz-Cornil, Isabelle Soulestin, Marion Eléouët, Jean-Franç Ois
source	Elsevier; Medline; PMC
abstract	Abstract Human and bovine respiratory syncytial viruses (HRSV and BRSV) are two closely related, worldwide prevalent viruses that are the leading cause of severe airway disease in children and calves, respectively. Efficacy of commercial bovine vaccines needs improvement and no human vaccine is licensed yet. We reported that nasal vaccination with the HRSV nucleoprotein produced as recombinant ring-shaped nanoparticles (NSRS) protects mice against a viral challenge with HRSV. The aim of this work was to evaluate this new vaccine that uses a conserved viral antigen, in calves, natural hosts for BRSV. Calves, free of colostral or natural anti-BRSV antibodies, were vaccinated with NSRS either intramuscularly, or both intramuscularly and intranasally using Montanide™ ISA71 and IMS4132 as adjuvants and challenged with BRSV. All vaccinated calves developed anti-N antibodies in blood and nasal secretions and N-specific cellular immunity in local lymph nodes. Clinical monitoring post-challenge demonstrated moderate respiratory pathology with local lung tissue consolidations for the non-vaccinated calves that were significantly reduced in the vaccinated calves. Vaccinated calves had lower viral loads than the non-vaccinated control calves. Thus NSRS vaccination in calves provided cross-protective immunity against BRSV infection without adverse inflammatory reaction.
has issue date	2010-05-07(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2010.03.008
bibo:pmid	20307593
has license	els-covid
sha1sum (hex)	3fb11a22a83515970d785114319200c4f7c69391
schema:url	https://doi.org/10.1016/j.vaccine.2010.03.008
resource representing a document's title	A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus
has PubMed Central identifier	PMC7115569
has PubMed identifier	20307593
schema:publication	Vaccine
resource representing a document's body	covid:3fb11a22a83515970d785114319200c4f7c69391#body_text
is schema:about of	named entity 'commercial' named entity 'generally' named entity 'SRS' named entity 'consolidations' named entity 'calves' named entity 'lymph nodes' named entity 'viral' named entity 'viral' named entity 'nasal secretions' named entity 'CIRCULATE' named entity 'RESPIRATORY SYNCYTIAL VIRUSES' named entity 'INFLAMMATORY REACTION' named entity 'RECOMBINANT' named entity 'VIROLOGICAL' named entity 'THEIR' named entity 'VIRUSES' named entity 'REACH' named entity 'LIVE' named entity 'ORGANIZATIONS' named entity 'SEVERE' named entity 'USES' named entity 'VIRAL ANTIGEN' named entity 'LUNG TISSUE' named entity 'PROBABLY' named entity '60%' named entity 'NANOPARTICLES' named entity 'SINGLE FRACTION' named entity 'INFECTION' named entity 'CONSERVED' named entity 'MORE THAN' named entity 'LEADING' named entity 'EVALUATE' named entity 'MODERATE' named entity 'BOVINE' named entity 'PREVALENCE' named entity 'AIRWAY DISEASE' named entity 'DURATION' named entity 'EITHER' named entity 'CLINICAL' named entity 'POST' named entity 'VACCINES' named entity 'VACCINE' named entity 'IMPACT' named entity 'POPULATIONS' named entity '28S' named entity 'CALVES' named entity 'NUCLEOPROTEIN' named entity 'IS A' named entity 'HOSTS' named entity 'HUMAN' named entity 'AVAILABLE' named entity 'NASAL' named entity 'WORLDWIDE' named entity 'AIM' named entity 'WORK' covid:arg/3fb11a22a83515970d785114319200c4f7c69391 named entity 'PARTIAL' named entity 'SUBUNIT VACCINE' named entity 'NEW' named entity 'RESPIRATORY DISEASES' named entity 'INFECTIONS' named entity 'NASAL SECRETIONS' named entity 'IN BLOOD' named entity 'HAVE' named entity 'EPIZOOTIC' named entity 'RESPIRATORY' named entity 'CHALLENGE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software